Characteristics and Absolute Survival of Metastatic Colorectal Cancer Patients Treated With Biologics: A Real-World Data Analysis From Three European Countries

Oppelt, Katja Anita; Kuiper, Josephina G.; Ingrasciotta, Ylenia; Ientile, Valentina; Herings, Ron M. C.; Tari, Michele; Trifirò, Gianluca; Haug, Ulrike

doi:10.3389/fonc.2021.630456

Cited by 7 publications

(10 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Resultsmentioning

confidence: 99%

“…22,23 Furthermore, research by Song et al shows AAV8 delivery of hAAT into mice can prevent the antibody development associated with delivery of the protein, a major concern with biologic therapeutics. [24][25][26][27][28][29][30][31][32] Previous efforts to achieve in vivo hAAT plasmid delivery using liposomal vectors have resulted in modest outcomes in animals. 33 Additionally, in a phase I clinical study, the hAAT levels achieved with this method were subtherapeutic.…”

Section: Lnp Formulation Containing Dspe-peg2000 and Dspc Fails To Tr...mentioning

confidence: 99%

See 1 more Smart Citation

In vivoassessment of triazine lipid nanoparticles as transfection agents for plasmid DNA

et al. 2022

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Lnp Formulation Containing Dspe-peg2000 and Dspc Fails To Tr...mentioning

confidence: 99%

In vivoassessment of triazine lipid nanoparticles as transfection agents for plasmid DNA

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Considering the anti-angiogenic agents, bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF), having a significant role in the treatment of metastatic CRC [ 17 ]. The biologic drug ramucirumab can also be administered as an angiogenesis inhibitor in metastatic CRC patients, and like bevacizumab, it is a fully humanized immunoglobulin G1 monoclonal antibody that binds with high affinity to the VEGFR-2 extracellular domain, blocking all VEGF ligands from binding to this target [ 18 , 19 ]. This drug is normally used with FOLFIRI to treat metastatic CRC when the cancer continues to progress during or after other treatments.…”

Section: Colorectal Cancer Therapeutic Challengesmentioning

confidence: 99%

“…This drug is normally used with FOLFIRI to treat metastatic CRC when the cancer continues to progress during or after other treatments. Another available biological drug is regorafenib (Stivarga) that acts as a multi-kinase inhibitor, namely through the inactivation of angiogenic and oncogenic kinases, such as VEGF 1–3, fibroblast growth factor receptor 1, EGFR, RAF, and tyrosine-protein kinase [ 18 , 20 ]. It is designed to treat patients with metastatic colon cancer whose cancer has continued to advance after approved standard therapies [ 18 , 20 ].…”

Section: Colorectal Cancer Therapeutic Challengesmentioning

confidence: 99%

Modulation of the Tumor Microenvironment by Microbiota-Derived Short-Chain Fatty Acids: Impact in Colorectal Cancer Therapy

Gomes

Rodrigues

Pazienza

et al. 2023

IJMS

View full text Add to dashboard Cite

Finding new therapeutic approaches towards colorectal cancer (CRC) is of increased relevance, as CRC is one of the most common cancers worldwide. CRC standard therapy includes surgery, chemotherapy, and radiotherapy, which may be used alone or in combination. The reported side effects and acquired resistance associated with these strategies lead to an increasing need to search for new therapies with better efficacy and less toxicity. Several studies have demonstrated the antitumorigenic properties of microbiota-derived short-chain fatty acids (SCFAs). The tumor microenvironment is composed by non-cellular components, microbiota, and a great diversity of cells, such as immune cells. The influence of SCFAs on the different constituents of the tumor microenvironment is an important issue that should be taken into consideration, and to the best of our knowledge there is a lack of reviews on this subject. The tumor microenvironment is not only closely related to the growth and development of CRC but also affects the treatment and prognosis of the patients. Immunotherapy has emerged as a new hope, but, in CRC, it was found that only a small percentage of patients benefit from this treatment being closely dependent on the genetic background of the tumors. The aim of this review was to perform an up-to-date critical literature review on current knowledge regarding the effects of microbiota-derived SCFAs in the tumor microenvironment, particularly in the context of CRC and its impact in CRC therapeutic strategies. SCFAs, namely acetate, butyrate, and propionate, have the ability to modulate the tumor microenvironment in distinct ways. SCFAs promote immune cell differentiation, downregulate the expression of pro-inflammatory mediators, and restrict the tumor-induced angiogenesis. SCFAs also sustain the integrity of basement membranes and modulate the intestinal pH. CRC patients have lower concentrations of SCFAs than healthy individuals. Increasing the production of SCFAs through the manipulation of the gut microbiota could constitute an important therapeutic strategy towards CRC due to their antitumorigenic effect and ability of modulating tumor microenvironment.

show abstract

“…In addition, general practitioner's prescriptions (from Arianna database) with related indication for use as well as electronic therapeutic plans (filled by the specialist and including information on drug prescribed, indication for use, drug dosages, and therapy duration) and results of diagnostic tests are collected in Caserta database. The Caserta LHU claims and General Practitioner Arianna databases have been shown to provide accurate and reliable information for pharmacoepidemiological research, as documented elsewhere [28][29][30][31][32]. In Caserta LHU DB, drug dispensing is coded using the Anatomical Therapeutic Chemical (ATC) classification system or specific Italian market authorization code (AIC), while indications for use and causes of hospitalizations are coded using the International Classification of Diseases, 9th revision, clinical modification (ICD9-CM).…”

Section: Data Sourcesmentioning

confidence: 99%

Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study

et al. 2022

Self Cite

View full text Add to dashboard Cite

Introduction Rheumatoid arthritis (RA) is associated with significant morbidity and economic burden. This study aimed to compare baseline characteristics and patterns of anti-inflammatory drug use and disease-modifying anti-rheumatic drug (DMARD) use among patients with RA in Southern Italy versus the United States. Method Using Caserta Local Health Unit (Italy) and Optum’s de-identified Clinformatics® Data Mart (United States) claims databases, patients with ≥ 2 diagnosis codes for RA during the study period (Caserta: 2010–2018; Optum: 2010–2019) were identified. Baseline patient characteristics, as well as proportion of RA patients untreated/treated with NSAIDs/glucocorticoids/conventional DMARDs (csDMARDs)/biological/targeted synthetic DMARDs (b/tsDMARDs) during the first year of follow-up, and the proportion of RA patients with ≥ 1 switch/add-on between the first and the second year of follow-up, were calculated. These analyses were then stratified by age group (< 65; ≥ 65). Results A total of 9227 RA patients from Caserta and 195,951 from Optum databases were identified (two-thirds were females). During the first year of follow-up, 45.9% RA patients from Optum versus 79.9% from Caserta were exclusively treated with NSAIDs/glucocorticoids; 17.2% versus 11.3% from Optum and Caserta, respectively, were treated with csDMARDs, mostly methotrexate or hydroxychloroquine in both cohorts. Compared to 0.6% of RA patients from Caserta, 3.2% of the Optum cohort received ≥ 1 b/tsDMARD dispensing. Moreover, 61,655 (33.7%) patients from Optum cohort remained untreated compared to 748 (8.3%) patients from the Caserta cohort. The subgroup analyses stratified by age showed that 42,989 (39.8%) of elderly RA patients were untreated compared to 18,666 (24.9%) young adult RA patients in Optum during the first year of follow-up. Moreover, a higher proportion of young adult RA patients was treated with b/tsDMARDs, with and without csDMARDs, compared to elderly RA patients (Optum<65: 6.4%; Optum≥65: 1.0%; P-value < 0.001; Caserta<65: 0.8%; Caserta≥65: 0.1%; P-value < 0.001). Among RA patients untreated during the first year after ID, 41.2% and 48.4% RA patients from Caserta and Optum, respectively, received NSAIDs, glucocorticoids, and cs/b/tsDMARDs within the second year of follow-up. Stratifying the analysis by age groups, 50.6% of untreated young RA patients received study drug dispensing within the second year of follow-up, compared to only 36.7% of elderly RA patients in Optum. Interestingly, more young adult RA patients treated with csDMARDs during the first year after ID received a therapy escalation to b/tsDMARD within the second year after ID in both cohorts, compared to elderly RA patients (Optum<65: 7.8%; Optum≥65: 1.8%; Caserta<65: 3.2%; Caserta≥65: 0.6%). Conclusions Most of RA patients, with heterogeneous baseline characteristics in Optum and Caserta cohorts, were treated with anti-inflammatory/csDMARDs rather than bDMARDs/tsDMARDs during the first year post-diagnosis, especially in elderly RA patients, suggesting a need for better understanding and dealing with barriers in the use of these agents for RA patients. Key Points • Substantial heterogeneity in baseline characteristics and access to bDMARD or tsDMARD drugs between RA patients from the United States and Italy exists. • Most of RA patients seem to be treated with anti-inflammatory/csDMARD drugs rather than bDMARD/tsDMARD drugs during the first year post-diagnosis. • RA treatment escalation is less frequent in old RA patients than in young adult RA patients. • An appropriate use of DMARDs should be considered to achieve RA disease remission or low disease activity.

show abstract

Characteristics and Absolute Survival of Metastatic Colorectal Cancer Patients Treated With Biologics: A Real-World Data Analysis From Three European Countries

Cited by 7 publications

References 24 publications

In vivoassessment of triazine lipid nanoparticles as transfection agents for plasmid DNA

In vivoassessment of triazine lipid nanoparticles as transfection agents for plasmid DNA

Modulation of the Tumor Microenvironment by Microbiota-Derived Short-Chain Fatty Acids: Impact in Colorectal Cancer Therapy

Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study

Contact Info

Product

Resources

About